Short answer
Vaxcyte, Inc. (PCVX) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 8.01 (Other Events). New ATM offering established Feb 24, 2026: up to $500M in common stock via Leerink Partners, replacing prior Jefferies facility.
Vaxcyte, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- New ATM offering established Feb 24, 2026: up to $500M in common stock via Leerink Partners, replacing prior Jefferies facility
- Placement agent fee up to 3.00% of gross proceeds: dilution cost to existing shareholders on any shares sold
- Prior Jefferies ATM (est. 2021) terminated after ~$270.3M raised: new facility resets capacity with a new counterparty
- No obligation to sell any shares: actual timing, price, and volume at company's discretion; no guaranteed capital raise
- Pre-clinical biotech using ATM for runway extension: watch for cadence of share sales as signal of cash burn vs. pipeline milestones
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vaxcyte, Inc. 8-K filings
Get the next PCVX 8-K as it lands
Follow PCVX for push alerts, or ask the research agent what this filing means.